An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).
- Registration Number
- NCT01076010
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Brief Summary
Open-label, multi-center extension treatment protocol to allow access to tivozanib and sorafenib for subjects who have participated on the AV-951-09-301 protocol. Eligible subjects who were randomized to receive sorafenib on AV-951-09-301 and had documented progression of disease will receive a tivozanib dose of 1.5 mg/day. Eligible subjects who were randomized to tivozanib or sorafenib in AV-951-09-301, and displayed clinical benefit and acceptable tolerability to treatment, will continue to receive tivozanib or sorafenib at the same dose and schedule as in AV-951-09-301.
- Detailed Description
This is an extension treatment protocol to allow access to tivozanib or sorafenib for subjects enrolled on AV-951-09-301(parent protocol). Subjects who failed sorafenib on the parent protocol will be offered tivozanib. Subjects who were randomized to tivozanib, and demonstrated clinical benefit and acceptable tolerability will be offered long-term access to tivozanib. Subjects who were randomized to sorafenib, and demonstrated clinical benefit and acceptable tolerability will be offered long-term access to sorafenib. Subjects who continue receiving sorafenib on this protocol and progress will be allowed to cross-over to tivozanib.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 277
-
The subject must have participated on Protocol AV-951-09-301, and must meet either of the following bulleted criteria:
- Demonstrated disease progression per RECIST during treatment with sorafenib, OR
- Demonstrated clinical benefit [complete response (CR), partial response (PR), or stable disease (SD) per RECIST] and acceptable tolerability after treatment with tivozanib or sorafenib on protocol AV-951-09-301.
-
Eastern Cooperative Oncology Group performance status ≤ 2 and life expectancy ≥ 3 months.
-
If female and of childbearing potential, documentation of negative pregnancy test prior to enrollment.
-
Ability to give written informed consent
-
Newly identified central nervous system (CNS) malignancies or documented progression of CNS metastases; subjects will be allowed only if the CNS metastases have been adequately treated with radiotherapy or surgery. For subjects receiving steroid therapy for allowed steroid maintenance therapy.
-
Duration since last dose on Protocol AV-951-09-301:
- For subjects continuing tivozanib or sorafenib (subjects who demonstrated clinical benefit and acceptable tolerability during treatment with tivozanib or sorafenib on protocol AV-951-09-301): more than 2 weeks since last dose of tivozanib or sorafenib.
- For subjects initiating tivozanib (ie demonstrated disease progression during treatment with sorafenib): more than 4 weeks since last dose of sorafenib. Subjects demonstrating disease progression due to CNS metastasis will be allowed up to 8 weeks since last dose of sorafenib in order to complete treatment for CNS metastasis.
-
Inadequate recovery from any prior surgical procedure or major surgical procedure within 4 weeks prior to administration of first dose of study drug.
-
Any of the following hematologic abnormalities:
- Hemoglobin < 9.0 g/dL
- Absolute neutrophil count < 1500 per mm3
- Platelet count < 75,000 per mm3
- Prothrombin time or Partial thromboplastin time >1.5 × upper limit of normal (ULN)
-
Any of the following serum chemistry abnormalities:
- Total bilirubin > 1.5 × ULN (or > 2.5 × ULN for subjects with Gilbert's syndrome)
- Aspartate aminotransferase or alanine aminotransferase > 2.5 × ULN (or > 5 × ULN for subjects with liver metastasis)
- Alkaline phosphatase > 2.5 × ULN (or > 5 × ULN for subjects with liver or bone metastasis)
- Creatinine > 2.0 × ULN
- Proteinuria > 3+ by urinalysis or urine dipstick
-
If female, pregnant or lactating.
-
Sexually active pre-menopausal female subjects (and female partners of male subjects) must use adequate contraceptive measures, while on study and for at least 50 days after the last dose of study drug. Sexually active male subjects must use adequate contraceptive measures, while on study and for at least 90 days after the last dose of study drug. All fertile male and female subjects,and their partners,must agree to use a highly effective method of contraception. Effective birth control includes (a) Intrauterine device plus one barrier method; or (b) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm). (Note: Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are not considered effective for this study).
-
Uncontrolled hypertension: systolic blood pressure > 150 mmHg or diastolic blood pressure >100 mmHg on 2 or more antihypertensive medications, documented on 2 consecutive measurements taken at least 24 hours apart.
-
Unhealed wounds (including active peptic ulcers).
-
Serious/active infection or infection requiring parenteral antibiotics.
-
Life-threatening illness or organ system dysfunction compromising safety evaluation.
-
Psychiatric disorder, altered mental status precluding informed consent or necessary testing.
-
Inability to comply with protocol requirements.
-
Treatment with another anti-cancer therapy or participation in another interventional protocol (excluding AV-951-09-301).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description First line sorafenib. Sorafenib The subjects who were randomized to sorafenib (continued from the parent Protocol AV-951-09-301) and demonstrated clinical benefit and acceptable tolerability were to be offered long-term access to sorafenib. Sorafenib crossover to tivozanib. Tivozanib The subjects who failed sorafenib (had Response Evaluation Criteria in Solid Tumors \[RECIST\] - defined progressive disease) on the parent protocol AV-951-09-301 will be offered tivozanib hydrochloride on Protocol AV- 951-09-902. Sorafenib crossover to tivozanib. Sorafenib The subjects who failed sorafenib (had Response Evaluation Criteria in Solid Tumors \[RECIST\] - defined progressive disease) on the parent protocol AV-951-09-301 will be offered tivozanib hydrochloride on Protocol AV- 951-09-902. First line tivozanib. Tivozanib The subjects who were randomized to tivozanib (continued from the parent Protocol AV-951-09-301) and demonstrated clinical benefit and acceptable tolerability in Protocol AV-951-09-301.
- Primary Outcome Measures
Name Time Method Number of Subjects With Adverse Events From enrollment assessed up to 3 years of treatment or until follow-up (up to 30 days end-of-trial visit after treatment discontinuation), whichever occurs earlier Number of subjects with Treatment-Related Adverse Events (AEs) as assessed by Common Terminology Criteria for Adverse Events v3.0
Number of Days Subjects Received Treatment in Each Treatment Arm From enrollment to until all subjects discontinue (due to documented progressive disease [PD] or unacceptable toxicities) or until 3 years after the first subject was enrolled in Protocol AV-951-09-902 Number of days subjects received treatment who were from Protocol AV-951-09-301 who either continued on tivozanib in this trial (subjects with first-line experience on tivozanib treatment), who crossed over from sorafenib to tivozanib in this trial (crossover subjects) participated in, and who continued on sorafenib in this trial (subjects with first-line experience on sorafenib treatment). Subjects could be discontinued due to unacceptable toxicities or clinical or documented PD
Total Dose Administered to Subjects in Each Treatment Arm (mg) From enrollment to until all subjects discontinue (due to documented PD or unacceptable toxicities) or until 3 years after the first subject was enrolled in Protocol AV-951-09-902 The total dose administered to subjects who were from Protocol AV-951-09-301 who either continued on tivozanib in this trial (subjects with first-line experience on tivozanib treatment), who crossed over from sorafenib to tivozanib in this trial (crossover subjects) participated in, and who continued on sorafenib in this trial (subjects with first-line experience on sorafenib treatment). Subjects could be discontinued due to unacceptable toxicities or clinical or documented PD
Average Daily Dose Administered to Subjects in Each Treatment Arm From enrollment to until all subjects discontinue (due to documented PD or unacceptable toxicities) or until 3 years after the first subject was enrolled in Protocol AV-951-09-902 The average daily dose administered to subjects who were from Protocol AV-951-09-301 who either continued on tivozanib in this trial (subjects with first-line experience on tivozanib treatment), who crossed over from sorafenib to tivozanib in this trial (crossover subjects) participated in, and who continued on sorafenib in this trial (subjects with first-line experience on sorafenib treatment). Subjects could be discontinued due to unacceptable toxicities or clinical or documented PD
Relative Dose Intensity (RDI) of Treatment Administered to Subjects in Each Treatment Arm From enrollment to until all subjects discontinue (due to documented PD or unacceptable toxicities) or until 3 years after the first subject was enrolled in Protocol AV-951-09-902 RDI is defined as 100% times the actual dose intensity divided by the intended dose intensity. The RDI of subjects who were from Protocol AV-951-09-301 who either continued on tivozanib in this trial (subjects with first-line experience on tivozanib treatment), who crossed over from sorafenib to tivozanib in this trial (crossover subjects) participated in, and who continued on sorafenib in this trial (subjects with first-line experience on sorafenib treatment). Subjects could be discontinued due to unacceptable toxicities or clinical or documented PD
Number of Cycles Subjects Received Treatment in Each Treatment Arm From enrollment to until all subjects discontinue (due to documented PD or unacceptable toxicities) or until 3 years after the first subject was enrolled in Protocol AV-951-09-902 Number of cycles subjects received who were from Protocol AV-951-09-301 who either continued on tivozanib in this trial (subjects with first-line experience on tivozanib treatment), who crossed over from sorafenib to tivozanib in this trial (crossover subjects) participated in, and who continued on sorafenib in this trial (subjects with first-line experience on sorafenib treatment). Subjects could be discontinued due to unacceptable toxicities or clinical or documented PD
- Secondary Outcome Measures
Name Time Method Duration of Response (DR) From the first documentation of objective tumor response to the first documentation of objective tumor progression, assessed up to treatment discontinuation or to death due to any reason or maximum up to 3 years, whichever occurs earlier DR was defined as the time from the first documentation of objective tumor response (confirmed CR or confirmed PR) according to RECIST (Version 1.0) to the first documentation of objective tumor progression or to death due to any reason. DR was calculated for the subgroup of subjects with a confirmed objective tumor response (PR or CR). CR is Disappearance of all target and non-target lesions and normalization of tumor marker levels. PR is At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Number of subjects with disease progression or death and censored endpoints were summarized and statistical analysis were performed for duration of response.
Progression-free Survival (PFS) From the date of first dose of study drug (tivozanib or sorafenib) in the AV-951-09-902 study to the first documentation of objective tumor progression or death due to any reason or maximum up to 3 years, whichever occurred first PFS was defined as the date of first dose of study drug to the first documentation of objective tumor progression or death due to any reason, whichever occurred first. For the crossover subjects and subjects with first-line experience on tivozanib treatment, the timeframe for PFS assessment started from the date of first dose of tivozanib in the AV-951-09-902 study. For subjects with first-line experience on sorafenib treatment, the timeframe for PFS assessment started from the date of first dose of sorafenib in the AV-951-09-902. Number of subjects with disease progression or death was summarized and statistical analysis were performed for PFS.
Number of Subjects With Objective Response Rate (ORR) Who Continued Treatment With Tivozanib or Sorafenib and Who Received Tivozanib After Failure of Sorafenib From Day 1 to the end of treatment (EOT) Visit, approximately every 8 weeks ORR is defined as the proportion of subjects with confirmed complete response (CR) or confirmed partial response (PR) according to RECIST (Version 1.0), relative to the total population of dosed subjects. CR is disappearance of all target and non-target lesions and normalization of tumor marker levels. At least a 30% decrease in the sum of the loading dose (LD) of target lesions, taking as reference the baseline sum LD. To allow long-term access to sorafenib for subjects who participated in Protocol AV-951-09-301 (NCT01030783), and demonstrated clinical benefit and acceptable tolerability to sorafenib.
Overall Survival (OS) From the date of first dose of study drug (tivozanib or sorafenib) in the AV-951-09-902 study to death due to any reason or maximum up to 3 years, whichever occurred first OS was defined as the time from the first dose of study drug (tivozanib or sorafenib) date on this study to date of death due to any cause. Number of subjects died or alive was summarized and statistical analysis were performed for OS.
Trial Locations
- Locations (75)
Site 122
🇨🇱Santiago, Chile
Site 441
🇷🇴Bucharest, Romania
Site 496
🇺🇦Donetsk, Ukraine
Site 123
🇨🇱Temuco, Chile
Site 182
🇺🇸Minneapolis, Minnesota, United States
Site 133
🇫🇷Saint Herblain Cedex, France
Site 402
🇧🇬Veliko Tarnovo, Bulgaria
Site 150
🇮🇳Kolkata, West Bengal, India
Site 450
🇷🇺Nizhny Novgorod, Russian Federation
Site 160
🇮🇹Arezzo, Italy
Site 411
🇨🇿Prague 8, Czechia
Site 403
🇧🇬Plovdiv, Bulgaria
Site 404
🇧🇬Sofia, Bulgaria
Site 460
🇷🇺Moscow, Russian Federation
Site 153
🇮🇳Pune, Maharashtra, India
Site 187
🇺🇸Dallas, Texas, United States
Site 442
🇷🇴Timisoara, Romania
Site 161
🇮🇹Pavia, Italy
Site 458
🇷🇺Moscow, Russian Federation
Site 465
🇷🇺St. Petersburg, Russian Federation
Site 451
🇷🇺Chelyabinsk, Russian Federation
Site 491
🇺🇦Chernihiv, Ukraine
Site 453
🇷🇺Moscow, Russian Federation
Site 462
🇷🇺Moscow, Russian Federation
Site 467
🇷🇺Omsk, Russian Federation
Site 480
🇷🇸Belgrade, Serbia
Site 482
🇷🇸Belgrade, Serbia
Site 495
🇺🇦Zaporizhia, Ukraine
Site 452
🇷🇺Kazan, Russian Federation
Site 464
🇷🇺Yaroslavl, Russian Federation
Site 456
🇷🇺Obninsk, Russian Federation
Site 483
🇷🇸Nis, Serbia
Site 498
🇺🇦Dniproperovsk, Ukraine
Site 172
🇬🇧Leicester, United Kingdom
Site 484
🇷🇸Sremska Kamenica, Serbia
Site 494
🇺🇦Kharkiv, Ukraine
Site 497
🇺🇦Uzhhorod, Ukraine
Site 191
🇮🇳Jaipur, Rajasthan, India
Site 152
🇮🇳Vellore, Tamil Nadu, India
Site 423
🇭🇺Budapest, Hungary
Site 184
🇺🇸Orlando, Florida, United States
Site 185
🇺🇸Los Angeles, California, United States
Site 400
🇧🇬Sofia, Bulgaria
Site 186
🇺🇸New York, New York, United States
Site 110
🇨🇦Montréal, Quebec, Canada
Site 156
🇮🇳Ahmedabad, Gujarat, India
Site 422
🇭🇺Pécs, Hungary
Site 151
🇮🇳Nashik, Maharashtra, India
Site 158
🇮🇳Lucknow, Uttar Pradesh, India
Site 162
🇮🇹Roma, Italy
Site 434
🇵🇱Bydgoszcz, Poland
Site 430
🇵🇱Warsaw, Poland
Site 443
🇷🇴Bucharest, Romania
Site 454
🇷🇺Moscow, Russian Federation
Site 459
🇷🇺Ufa, Republic Of Bashkortostan, Russian Federation
Site 455
🇷🇺Ekaterinburg, Russian Federation
Site 461
🇷🇺Moscow, Russian Federation
Site 463
🇷🇺Pyatigorsk, Russian Federation
Site 457
🇷🇺Rostov-on Don, Russian Federation
Site 466
🇷🇺St. Petersburg, Russian Federation
Site 490
🇺🇦Ivano-Frankivsk, Ukraine
Site 170
🇬🇧Cambridge, United Kingdom
Site 444
🇷🇴Brasov, Romania
Site 435
🇵🇱Olsztyn, Poland
Site 432
🇵🇱Bialystok, Poland
Site 431
🇵🇱Gdansk, Poland
Site 436
🇵🇱Warsaw, Poland
Site 421
🇭🇺Kaposvár, Hungary
Site 440
🇷🇴Bucharest, Romania
Site 492
🇺🇦Dniproperovsk, Ukraine
Site 154
🇮🇳Delhi, India
Site 433
🇵🇱Poznan, Poland
Site 481
🇷🇸Belgrade, Serbia
Site 493
🇺🇦Donetsk, Ukraine
Site 401
🇧🇬Varna, Bulgaria